

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Xunfei Healthcare Technology Co., Ltd.

訊飛醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2506)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

The board (the “**Board**”) of directors (the “**Director(s)**”) of Xunfei Healthcare Technology Co., Ltd. (the “**Company**” or “**Xunfei Healthcare**”, together with its subsidiaries and consolidated affiliated entities, collectively the “**Group**”) hereby announces the unaudited consolidated results of the Group for the six months ended June 30, 2026 (the “**Reporting Period**”). This announcement complies with the requirements of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) in relation to the information to be included in the preliminary announcement of interim results. These interim results have been reviewed by the audit committee of the Company (the “**Audit Committee**”).

FINANCIAL HIGHLIGHTS


	Six months ended June 30,		Year-on-year change
	2026	2025	
	<i>(RMB'000)</i>		
Revenue	446,116	298,552	49.4%
Gross profit	236,111	153,868	53.5%
Loss before tax	(67,624)	(100,134)	(32.5)%
Loss for the period	(48,100)	(82,276)	(41.5)%
Net loss attributable to owners of the parent company	(59,303)	(74,086)	(20.0)%

MANAGEMENT DISCUSSION AND ANALYSIS

In the first half of 2026, medical large models moved from a phase of technological exploration to a new stage of large-scale implementation, with vertical medical large models evolving towards multi-modal fusion and multi-AI agent collaboration. The continuous issuance of supportive national policies has accelerated the deep integration of artificial intelligence with public health, clinical diagnosis and treatment, and health management, providing a solid policy foundation and broad development space for the Company to deepen its presence in the smart healthcare market. Driven by technology innovation, policy support, and the demand for high-quality healthcare development, the Company's various businesses have encountered opportunities for accelerated development. Leveraging its leading medical large model technology and professional medical knowledge system, the Company continues to consolidate its core competitive advantages. With large model technology at its core, the Company has iteratively upgraded its three product systems—AI Medical Assistant, AI Health Partner, and AI Digital Base—and built a full-scenario AI empowerment matrix covering medical institutions, residents, and the government. The related products have achieved significant results in improving hospital operational efficiency, supporting residents' health management, and empowering industry supervision, laying a solid foundation for the Company's sustained high-quality development.

I. Core Technologies

Since the release of the industry's only medical large model trained on fully domestic computing power in 2023, the Company has continuously delved deeper into areas such as the construction of high-quality datasets, training of hospital-specific models, and R&D of medical professional AI agents, and has made continuous breakthroughs in key technical directions such as evidence-based inference and health interaction. In 2026, the Spark Medical Model V3.5 was officially released, with its core capabilities achieving a further leap and its technological level consistently remaining at the forefront of the industry.



Driven by continuous innovation and large-scale application, the Company's enduring world leadership stems from a double-helix evolutionary system built on a "technology foundation + closed-loop data ripple". On one hand, a fully domestic computing architecture, an authoritative medical knowledge base, and high-quality de-identified clinical data collectively form the Company's solid technology foundation. Leveraging this foundation, the Company has built systematic competitive barriers in underlying technological dimensions such as medical knowledge augmentation, deep reasoning architecture, and reinforcement learning from expert thinking chains. At the same time, it has established a knowledge reflection mechanism based on medical logic, a professionalism-oriented comment model, and a rationality-oriented process incentive model, comprehensively enhancing the medical large model's professionalism, operational safety, and clinical interpretability. On the other hand, with the large-scale deployment of products like the General Practice CDSS across the nation, over 1.7 million real-world diagnostic interactions per day are continuously accumulating high-value multi-modal model experience. In the vast majority of scenarios, the model's analytical results achieve a consistency rate of up to 95% with the diagnostic conclusions of practicing physicians, enabling the efficient accumulation and standardized retention of high-quality clinical diagnosis and treatment experience. In approximately 5.0% of complex cases, the system automatically triggers a review by a senior physician, precisely identifies key differences, and performs deep calibration using authoritative knowledge such as clinical guidelines and expert consensus. This creates a self-driven, dynamic learning loop that evolves from clinical practice to model improvement. With each cycle of feedback, the model continuously strengthens itself, building a hard-to-replicate evolutionary capability. This has laid a solid foundation for the iterative capability leaps of the Spark Medical Model across multiple generations.

(1) *Full-Stack Upgrade of Spark Medical Model X2: Industry-Leading Strength Validated by Authoritative Evaluations*

In February 2026, the Spark Medical Model X2 completed its iterative upgrade. The model encompasses six core capabilities: massive medical knowledge Q&A, complex medical language comprehension, professional medical document generation, medical diagnosis and treatment plan recommendations, multi-round medical dialogues, and multi-modal medical interactions. Its overall performance improved from 91.2% to 91.6%, continuing to lead the industry. In terms of technical architecture, the Spark Medical Model X2 adopts a 293B MoE sparse architecture, combined with multiple engineering innovations such as weight quantization and low-precision KVCache, enabling efficient deployment on domestic platforms with a 50.0% improvement in inference performance compared to the previous generation.

The Spark Medical Model X2 has demonstrated excellent performance on key medical tasks: it achieved a rationality rate of 90.1% for intelligent analysis of resident health records, 89.2% for physical examination report interpretation, 92.7% for exercise and diet guidance recommendations, 92.4% for Top 5 auxiliary diagnosis and treatment plans, and an accuracy rate of 94.1% for intelligent medication review. Its comprehensive capabilities in core scenarios significantly surpass leading domestic and international large models. By virtue of its full-stack technical capabilities and mature implementation experience in medical scenarios, the Spark Medical Model was the first to pass the authoritative evaluation and verification by the Shanghai Medical Large Model Application Testing and Verification Center (上海市醫療大模型應用檢測驗證中心). It received all “A” ratings for tasks related to public health and well-being, such as resident health analysis, physical examination report interpretation, and exercise and diet recommendations, with its professional performance ranking at the forefront of the industry. This fully demonstrates the model’s first-mover advantage, robust technical strength, and maturity in compliant implementation, building a solid foundation for its subsequent large-scale deployment and application in multiple scenarios.

(2) *Release of Upgraded Spark Medical Model V3.5: First to Reach Practical Threshold for Core Industry-Demand Capabilities*

In June 2026, the Company officially released the Spark Medical Model V3.5, trained on fully domestic computing power. The model comprehensively upgrades multi-modal capabilities in voice recognition, imaging-assisted diagnosis, and medical semantic understanding. It is the first to break through the practical implementation threshold in real-world medical scenarios for far-field multi-speaker voice recognition, automatic medical record generation, and automatic imaging report generation, with its imaging quality control capabilities surpassing the level of expert consultations.

Leveraging domestic computing platforms, the model has implemented efficient long-text training technology, increasing the throughput for long-context medical inference by 4.5 times. The average performance across its six core capabilities improved from 91.6% to 92.4%. It is highly adaptable to the needs of hospitals and regional healthcare for localized deployment and training based on local data. Meanwhile, through algorithmic iterations, high-quality medical data, and evidence-based reinforcement learning capabilities, the capabilities of AI agents for medical scenarios have been comprehensively enhanced, leading to a significant improvement in the practical capabilities of the entire medical product line.

In terms of performance on core medical tasks, the comprehensive performance of the Spark Medical Model V3.5 in key scenarios such as medical Q&A, document generation, auxiliary diagnosis, and multi-modal interaction significantly surpasses leading domestic and international large models, including GPT-5.5, DeepSeek-V4-Pro, and Qwen3.7-Max. According to the authoritative assessment in IDC's "China Medical Large Model Technology Assessment, 2026", the Spark Medical Model ranks first in the industry in terms of comprehensive strength. This assessment covered 15 core technical indicators. The model ranked first in the evaluation of 12 sub-capabilities, including auxiliary diagnosis, medical record generation, health consultation, post-discharge management and follow-up. It performed best in the dimensions of product implementation, operational safety, and large-scale application capability, fully verifying its leading technical strength and scenario adaptability. In addition, the model topped the list in the Shanghai Artificial Intelligence Laboratory's MedBench evaluation with a score of 98.9, ranking first in the industry across several core dimensions, including medical scenario perception and interaction, multi-AI agent collaboration in healthcare, and medical safety, ethics, and compliance.

During the Reporting Period, the upgrade of Spark Medical Model V3.5 achieved an innovative breakthrough in multi-modal technology, deeply integrating voice, imaging, and semantics supported by fully domestic computing power. It comprehensively enhanced the operational capabilities of AI agents in medical scenarios, achieved leapfrog breakthroughs from 0 to 1 in multiple capabilities within the two core tracks of clinical diagnosis and treatment for doctors and health management for residents, and was the first to meet the industry standard for large-scale practical implementation.

(3) ***Continuously Promoting the Standardized Development of Medical Large Models: Continuously Deepening Standards Development, Scientific Research and Innovation, and Ecosystem Collaboration***

In terms of standards system development: The Company continued to play a leading role in the industry, further improving the standards system for medical large models. During the Reporting Period, two group standards, the “Specification for Construction of Healthcare Portrait System (《醫療健康畫像體系構建規範》)” (T/ISC 0112-2026) and the “Method for Evaluating the Capability and Effect of Large Models Based on Healthcare Portrait (《基於醫療健康畫像的大模型能力效果評估方法》)” (T/ISC 0110-2026), were officially released. These were led by Xunfei Healthcare, in collaboration with the China Academy of Information and Communications Technology (CAICT), relevant national and local health commissions, the People’s Medical Publishing House, the Chinese Medical Association Publishing House, and over 30 top national medical institutions, including Peking Union Medical College Hospital and Beijing Anzhen Hospital. This initiative established the first standard framework covering the construction of healthcare portrait system and the capability evaluation of medical large models, forming a “system construction + capability evaluation” dual-engine standards system. It further improved the quality control, security governance of healthcare portraits, and the evaluation methods for medical large model capabilities, providing crucial standard support for the standardized development and large-scale application of medical artificial intelligence.

In terms of scientific research and innovation: The Company continued to strengthen its national-level scientific research capabilities and actively served the construction of the national public health system. The “Artificial Intelligence (AI)-Assisted Epidemiological Investigation System,” jointly developed by the Public Health Emergency Center of the Chinese Center for Disease Control and Prevention (lead) and Xunfei Healthcare (core technical support), won the Gold Award at the 2nd “Chuang Qing Chun (創青春)” National Youth Innovation Competition for the Health Industry. An agreement of intent for the industrialization of the research results was signed concurrently, marking the official entry of this national-level scientific achievement into the nationwide large-scale promotion phase. The project originated from the “New Generation Artificial Intelligence” major project under the Sci-Tech Innovation 2030 Agenda. The Company was deeply involved in the core technology R&D, achieving significant breakthroughs in key technical areas for epidemiological investigation scenarios, such as specialized medical voice recognition, full-process intelligent human-computer interaction, and multi-modal intelligent data collection. This provided an innovative practice for empowering the construction of the public health emergency system with artificial intelligence and further enhanced the Company’s technical influence and industrialization capabilities in major national scientific research projects.

In terms of business collaboration: The Company continued to deepen collaborative innovation with universities, research institutes, and leading medical institutions. It has established close cooperative relationships with several universities and Class A tertiary hospitals, including Zhejiang University, Qilu Hospital of Shandong University, Hainan General Hospital, and the First Affiliated Hospital of the University of Science and Technology of China. It released the “Hehe Huiyi (和合慧醫)” Knowledge Graph 2.0, the largest known Chinese clinical medical knowledge graph in the PRC, and simultaneously launched a new generation of primary care AI-assisted diagnosis and treatment systems, a whole-course disease management large model, and a series of clinical AI agents. This achieves deep integration of cutting-edge AI technology and authoritative medical knowledge in real-world diagnosis, treatment, and health management scenarios, continuously promoting the accessibility of quality medical resources, improving the quality and efficiency of clinical diagnosis and treatment, and advancing the large-scale implementation of medical artificial intelligence.

(4) *Advancing Cutting-Edge Technology and Practical Applications: Solidifying Core Advantages in the Large Model Industry Deployment*

Currently, the Company’s medical LLMs continue to maintain the following advantages in terms of industry application:

Multi-modal large model technology and systematic innovation capabilities: Achieved an innovative breakthrough in multi-modal technology with deep integration of voice, imaging, and semantics supported by fully domestic computing power, developed evidence-based reasoning technology for complex tasks featuring “evidence alignment — reflective verification — expert reinforcement”, and comprehensively advanced the capabilities of the large model’s clinical AI agents, becoming the first in the industry to cross the practical threshold for far-field multi-speaker voice recognition, automatic medical record generation, and automatic imaging report generation in real-world medical scenarios, thereby providing solid support for the high precision and multi-scenario adaptability of medical products.

Unique high-barrier data and knowledge accumulation in the industry: Achieved cross-modal alignment of data such as voice, images, and medical record text. The Spark Medical Model is continuously upgraded based on high-quality multi-modal medical datasets and an authoritative evidence-based medical knowledge base, learning clinical features from voice, imaging, and medical records in real clinical scenarios every day. Relying on the long-term accumulation of high-value medical resources, we have built a unique model iteration flywheel and autonomous evolution barrier in the industry.

Systematic innovation capabilities combining general and specialized applications: Deeply integrated multi-modal capabilities of medical voice recognition, imaging-assisted diagnosis, and medical semantic understanding, being the first in the industry to break through the practical threshold for far-field multi-speaker voice recognition and automatic medical record generation in real-world medical scenarios. Building on imaging quality control that surpasses the level of expert consultations, the Spark Medical Model deeply integrates imaging recognition with diagnostic and treatment reasoning capabilities, enabling its imaging report generation capability to cross the practical threshold for the first time in the industry.

Fully localized and self-controllable hardware and software route: We possess a complete, integrated technical solution for efficient training and inference based on domestic computing platforms such as Huawei Ascend. We are the first to achieve efficient long-text training with DSA (Dynamic Sparse Attention) and MTP (Multi-Token Prediction) on domestic computing platforms, increasing inference throughput in long-context medical scenarios by 4.5 times. This provides strong underlying technical support for localized model deployment and efficient iteration in hospitals and regional healthcare.

Unique system for large-scale deployment of core technologies in the industry: Leveraging the full-stack underlying capabilities of the Spark Medical Model, we have built a unique, end-to-end, replicable, and highly adaptable deployment and services system for medical AI. As one of the few companies capable of large-scale, nationwide commercialization of medical AI technologies in China, we have built a complete closed-loop system encompassing demand response, technology implementation and continuous iteration. We have successfully provided stable and standardized technical services to a massive user base, including graded hospitals, primary healthcare institutions, and regional imaging clouds, accumulating profound real-world clinical practice experience.

The enhancement of its core technology and product capabilities is attributable to the Company's unswerving investment in research and development (R&D). For the six months ended June 30, 2026, total R&D investment (including R&D expenses and development expenditures) was RMB194.8 million, an increase of 45.1% compared to the same period in 2025 (of which R&D investment in core technology amounted to RMB48.7 million, remaining largely unchanged from the prior period), accounting for 43.7% of the total revenue for the six months from January to June 2026.

II. BUSINESS REVIEW

In the first half of 2026, the Company actively pursued market expansion and continued to grow its customer base. As of June 30, 2026, the Company provided products and services to over 77,000 primary healthcare institutions, covering 828 districts and counties across 31 provinces, as well as more than 700 graded hospitals. The extensive market coverage underscores the technological leadership and market competitiveness of our AI-powered medical products. It also highlights the efficiency of our marketing system, laying a solid foundation for the next phase of rapid business development.

Leveraging its leading technological capabilities, extensive customer base, and brand recognition, the Company continues to improve its operational efficiency and seize new profit opportunities through synergistic commercialization strategies. For the six months ended June 30, 2026, the Company recorded revenue of RMB446.1 million, representing an increase of 49.4% as compared with the revenue of RMB298.6 million during the same period last year. For the six months ended June 30, 2026, the Company's gross profit was RMB236.1 million, reflecting an increase of 53.5% as compared with that of the same period last year. Our gross profit margin was 52.9%, maintaining at a reasonable high level with an increase of 1.4 percentage points from that of the same period last year, mainly due to the increase in the gross profit margin of the AI Digital Base business. As its product portfolio expands and matures, the Company anticipates rapid revenue growth alongside a relatively stable gross profit margin level.


For the six months ended June 30, 2026, the Company's revenue was primarily derived from AI Medical Assistant and AI Health Partner businesses. The following table sets out a breakdown of its revenue by business segment for the periods indicated:

	Period ended June 30							
	2026				Change			
					2025 (As restated)			
	Revenue	Percentage	Gross	Gross profit	Revenue	Percentage	Gross	Gross profit
	RMB in	of total	profit	margin	RMB in	of total	profit	margin
	thousands	revenue	RMB in		thousands	revenue	RMB in	
		%	thousands	%		%	thousands	%
AI Medical Assistant	201,562	45.2%	112,981	56.1%	136,674	45.8%	74,939	54.8%
AI Health Partner	182,387	40.9%	92,944	51.0%	104,253	34.9%	64,003	61.4%
AI Digital Base	62,167	13.9%	30,186	48.6%	57,625	19.3%	14,926	25.9%
Total	<u>446,116</u>	<u>100.0%</u>	<u>236,111</u>	<u>52.9%</u>	<u>298,552</u>	<u>100.0%</u>	<u>153,868</u>	<u>51.5%</u>

To align with the Company’s medium-and long-term strategic development, focus on improving the quality and efficiency of its core AI medical business, and further optimize resource allocation, the Company has integrated and upgraded its original four business lines into three major business segments: AI Medical Assistant, AI Health Partner, and AI Digital Base. Among them, “AI Medical Assistant” has taken over the business of the former primary solutions and hospital solutions; “AI Health Partner” corresponds to the former patient management services business; and “AI Digital Base” corresponds to the former regional solutions business.

Closely upholding its mission of becoming “an AI Medical Assistant for every doctor and an AI Health Partner for everyone”, the Company, based on industry-leading artificial intelligence technology and in-depth industry insights, has created the AI Medical Assistant, AI Health Partner and AI Digital Base to empower medical institutions, patients and governments with AI, with its services mainly including:

1. AI Medical Assistant: Providing an intelligent support system for medical institutions to improve medical service quality, patient satisfaction, and management efficiency;
2. AI Health Partner: Providing patients with AI services throughout their entire life cycle, including the cloud medical imaging platform for auxiliary diagnosis, AI post-discharge patient management services, intelligent medical devices (intelligent hearing aids and AI blood pressure monitors), and the home health consultation and management APP (Xunfei Xiaoyi);
3. AI Digital Base: Providing AI Digital Base for the government to strengthen primary healthcare services, enhance disease prevention and control capabilities, and improve regional medical collaboration and health levels;



Driven by the dual engines of the “Digital China” strategy and the “Healthy China” initiative, China continually strengthened the deep integration and application of artificial intelligence in the healthcare sector. Since 2026, China has introduced a series of top-level designs and implementation policies to comprehensively strengthen the development of new healthcare infrastructure. By leveraging artificial intelligence and digital technologies, these initiatives aim to optimize medical resource allocation, facilitate the flow of quality resources to grassroots levels, and deepen public health reforms, providing all-around support for the high-quality development of public hospitals and the enhancement of primary healthcare capabilities.

In April 2026, the National Health Commission and the National Administration of Traditional Chinese Medicine launched a three-year action plan (2026–2028) to improve the quality of medical care in primary healthcare institutions. The plan aims to establish a basic medical quality management system for primary healthcare institutions nationwide by the end of 2028, incorporating village clinics and community health service stations into the system. The document also calls for strengthening the intelligent construction of county-level medical communities and primary healthcare institutions, and promoting the use of artificial intelligence to empower quality management in primary care.

In June 2026, the General Office of the National Health Commission issued the “Notice on Further Improving the Urban Community Health Service System and Enhancing Service Capabilities (《關於進一步健全城市社區衛生服務體系提升服務能力的通知》),” which identifies digitalization and intelligence as key measures to improve the quality and efficiency of primary care and promotes the digital and intelligent transformation of community health services. The document proposes supporting the large-scale application of medical artificial intelligence in community health institutions, promoting tools such as AI-assisted diagnosis, intelligent prescription audit, and voice-based electronic medical records to reduce the burden on primary healthcare workers and improve diagnostic and treatment efficiency; leveraging digitalization to improve basic public health and family doctor contract services, and achieving efficient health follow-ups and tiered health management for residents. It encourages the use of AI for full-process intelligent quality control of medical records, prescriptions, and doctor’s orders to standardize primary medical documentation. The policy also requires integrating the information systems of communities and higher-level hospitals, unifying data standards, promoting the mutual interoperability and recognition of examination and test results, and building a collaborative digital network for hierarchical diagnosis and treatment.

In July 2026, the State Council issued the “Notice on the ‘15th Five-Year Plan’ for National Health (《國民健康「十五五」規劃》),” advancing the digital and intelligent construction of national health by building a national platform for cross-provincial sharing of smart health examination and test results, enabling real-time access to medical images, mutual recognition of test results, and linkage of public health information. Strictly ensure information security and privacy protection. Promote real-time access for residents to their electronic health record homepage data. Advance the construction of intelligent application systems for compact county-level medical communities. Implement intelligent and embedded supervision based on electronic medical record information, and orderly promote the application of digital and intelligent technologies in scenarios such as auxiliary diagnosis and treatment, precision medicine, health management, medical insurance services, and elderly and disabled care.

Against the backdrop of national strategic guidance, continuous policy improvement, and the implementation of application scenarios, artificial intelligence is transforming from a technical tool into a core force for reshaping the healthcare service system. The Company’s long-standing strategic direction is highly aligned with the medium-and long-term policies of the national healthcare system reform. Guided by national strategies such as the project to strengthen primary healthcare, the construction of compact county-level medical communities, the digital and intelligent transformation of healthcare, and the regulated development of AI-empowered healthcare, the Company will leverage its leading medical AI technology and full-scenario solutions to seize industry development opportunities and promote large-scale implementation with key base cities as fulcrums. Currently, AI Medical Assistant is in a window of opportunity for development, while the AI Health Partner has become a key theme in policy.

(1) AI Medical Assistant: Continuously expanding its scope based on the “General Practice CDSS”

General Practice CDSS for Primary Care: The General Practice CDSS is a core artificial intelligence medical product designed for primary care scenarios. Powered by the continuously upgraded Spark Medical Model, the General Practice CDSS has achieved a comprehensive evolution of its core capabilities. It has newly expanded into innovative application scenarios driven by the large model, including medical record generation, diagnostic reasoning, interpretation of examination and test reports, medical knowledge Q&A, and AI-assisted traditional Chinese medicine diagnosis and treatment. It has also completed iterative upgrades of its two technical solutions for multi-source data auxiliary diagnosis and intelligent prescription audit. The product can empower primary healthcare services in an all-round way, effectively improving the diagnostic and treatment capabilities, service quality, and efficiency of primary care institutions, significantly reducing the risks of misdiagnosis, missed diagnosis, and medication errors, and strengthening the safety line of defense for primary medical care.

From July 15 to 16, the Department of Primary Health of the National Health Commission held a promotion meeting on digital and intelligent empowerment of primary healthcare and the 2026 national primary healthcare policy training class in Hefei, Anhui. The meeting systematically deployed key tasks for the digitalization of primary healthcare nationwide and clarified the implementation path for the high-quality development of primary medical and health services. A number of benchmark achievements with significant demonstration value were showcased at the meeting, including the results of the regular implementation and application of the “General Practice CDSS” general practice auxiliary diagnosis system in benchmark regions across the country such as Anhui, Zhejiang, and Jiangxi; the Anhui provincial imaging cloud platform, the largest of its kind in the country, constructed and operated by Xunfei Healthcare; and the Anhui provincial consultation and referral service platform covering five levels: provincial, municipal, county, township, and village, intuitively demonstrating the mature and effective implementation of regional primary healthcare digitalization. After long-term practice and refinement in multiple regions and clinical scenarios, the Company’s integrated primary digital and intelligent service system continues to release its empowering value. In areas such as improving the quality and efficiency of primary care, balancing regional medical resources, and upgrading family doctor contract services, it has formed a mature, replicable, quantifiable, and scalable operational service model.

During the Reporting Period, the Company continued to advance the construction of the Hefei pilot base project, positioning it as a key support platform for the engineering verification, scenario-based refinement, and large-scale delivery of medical artificial intelligence products. Focusing on scenarios such as primary care auxiliary diagnosis, multi-source data reasoning, prescription audit, interpretation of examination and test reports, medical knowledge Q&A, and AI-assisted traditional Chinese medicine diagnosis, the Company promoted the deep integration of large model capabilities with real-world primary care workflows. Through pilot verification, the Company has further strengthened its closed-loop capabilities, from algorithm capabilities, data adaptation, system integration, and deployment delivery to application feedback, providing support for the replication and promotion of the General Practice CDSS in multi-regional and multi-level primary healthcare institutions nationwide. The Company cooperated with the China Health Education Center (中國健康教育中心) to build an authoritative health knowledge platform that integrates health policies, technical guidelines, and health education materials, enhancing the professional health service capabilities of primary healthcare personnel while providing urban and rural residents with scientific, authoritative, personalized, convenient, and accessible health education and guidance services.

As of June 30, 2026, the General Practice CDSS has covered 31 provinces and cities and 828 districts and counties across China, serving over 77,000 primary healthcare institutions. To date, it has provided over 1.2 billion AI-assisted diagnostic suggestions and assisted in generating more than 490 million standardized electronic medical records. Meanwhile, the system has identified over 130 million inappropriate prescriptions and corrected more than 2.07 million clinically valuable diagnoses through alerts by the General Practice CDSS, demonstrating its powerful value in large-scale application.

In the future, the Company will continue to leverage the engineering verification capabilities of the Hefei pilot base project, combined with the R&D accumulation from the national key R&D program “Auxiliary Diagnosis Robot for Primary Healthcare Institutions” in areas such as primary care-specific large models, auxiliary diagnosis hardware and software systems, cloud-edge collaborative intelligent computing platforms, standard specifications, and application evaluation systems. This will continuously drive the evolution of the General Practice CDSS towards higher accuracy, stronger interpretability, better process integration, and broader scenario coverage, thereby helping to enhance primary healthcare services capabilities and the sinking of high-quality medical resources.

Digital and Intelligent Family Doctor: Focusing on the two core scenarios of family doctor contract services and refined chronic disease management, it integrates multi-dimensional data sources such as public health, clinical diagnosis and treatment, and resident health records to build a dynamic resident health portrait and an intelligent chronic disease risk assessment system, continuously promoting the upgrade of primary healthcare services towards intelligence, efficiency, and precision. The product leverages large model capabilities to connect the service chain, building a closed loop of proactive resident health management and continuous services. It drives the transformation of the traditional family doctor contract model into a new model of proactive prediction, continuous service, and quantifiable assessment, creating a replicable and scalable primary digital and intelligent health service system.

For residents, the product transforms professional clinical data into easy-to-understand health information, providing 7x24 personalized AI health consultation and continuous health intervention management services for the entire population. For high-risk health issues, the system can automatically connect with real family doctors, forming a closed-loop smart family doctor service model of “AI-first service + human-backed support.” This achieves a closed-loop smart family doctor health service where residents’ health problems can be asked at any time, are managed, and are followed up, effectively enhancing residents’ sense of gain from contracted services.

For family doctors, the product provides full-process intelligent empowerment tools. By automatically generating pre-consultation health summaries to improve reception efficiency, intelligently creating tiered to-do lists to prevent missed tasks, and managing key chronic disease populations in layers supplemented by batch intelligent follow-ups, it comprehensively reduces the administrative workload of family doctors and significantly enhances the overall efficiency of primary care services and public health management.

During the Reporting Period, the Digital and Intelligent Family Doctor accelerated its nationwide large-scale deployment and has now been implemented in over 120 key districts and counties in more than 10 provinces and cities, including Hainan Province, Longhua District and Bao'an District in Shenzhen, Tongzhou District in Beijing, Hefei City, and Jiuquan City. In addition, the Company undertook the development of the satisfaction survey system for residents contracted with family doctors for the Medical Administration Center of the National Health Commission (國家衛健委醫政醫管中心), helping to further strengthen the implementation of family doctor contracting services nationwide, promote the fulfillment of such contracts, and enhance the experience of contracted residents.

Hospital Medical Assistant: Targeting graded hospitals, the Company provides “three-in-one” integrated smart hospital solutions encompassing smart services, smart medical care, and smart management, with the aim of improving patient experience, enhancing the quality of medical services, and innovating big data applications. Currently, the solutions have been implemented in over 700 hospitals nationwide, including the First Affiliated Hospital of the University of Science and Technology of China, Peking Union Medical College Hospital, West China Hospital of Sichuan University, Qilu Hospital of Shandong University, Shandong Provincial Hospital, and the First Affiliated Hospital of Anhui Medical University, helping nearly 20 hospitals pass the Level 5 electronic medical record and Level 3 smart service evaluations.

During the Reporting Period, the Sixth Affiliated Hospital of Sun Yat-sen University launched the “AI Medical Assistant” system. With the Spark Medical Model as its technical foundation, the system relies on the rich medical knowledge base and instruction orchestration embedded in the model to achieve real-time sharing and interaction of multi-modal diagnosis and treatment data, empowering clinical processes such as admission, ward rounds, surgery, and discharge. The product is now in regular use in 7 wards and 20 clinical teams, including colorectal surgery and medical oncology. As an essential application for the digital transformation of hospitals, AI Medical Assistant, with the core advantages mentioned above, has garnered high clinical recognition, strong scenario stickiness, and good replicability and scalability. Moving forward,

the Company will continue to expand the specialty coverage and functional boundaries of its products, refine core capabilities, further broaden its commercialization space, and solidify its long-term growth momentum.

In addition, focusing on the core pain points and essential needs of empowering clinical research data and translating medical achievements in graded hospitals, the Company has deeply integrated the Spark Medical Model with core medical big data technologies to self-develop a hospital-wide AI research data platform. Using the collaboration project with Peking Union Medical College Hospital as a benchmark model, the Company has continuously expanded its partnership landscape, successively implementing projects in leading provincial and municipal hospitals such as the Affiliated Hospital of Hebei University in Hebei Province, Dongguan People's Hospital in Guangdong Province, and the First Affiliated Hospital of the University of Science and Technology of China. This has effectively broken down the barriers between clinical diagnosis and treatment and research applications, enabling the deep release of clinical data value and driving the continuous and large-scale growth of related businesses.

For the six months ended June 30, 2026, the Company recorded revenue of RMB201.6 million from AI Medical Assistant, representing an increase of 47.5% as compared to the same period in 2025, and accounting for 45.2% of its total revenue for the first half of 2026.

(2) *AI Health Partner: Extending from In-hospital Management to Home Health*

In the C-end market, Xunfei Healthcare has developed the AI Health Partner for discharged patients and healthy individuals. Leveraging the cloud medical imaging platform for auxiliary diagnosis to provide digital imaging services and gradually build personal health records. Combined with the AI post-discharge management system and the Xunfei Xiaoyi C-end platform to undertake full-cycle health management services such as regular health consultations and rehabilitation follow-ups. Paired with self-developed intelligent medical devices, it implements an integrated hardware-software home health solution, extending medical services from in-hospital clinical diagnosis and treatment to the full spectrum of out-of-hospital home health management scenarios.

Cloud Medical Imaging Platform for Auxiliary Diagnosis: During the Reporting Period, the Company continued to promote the interoperability of medical imaging data, mutual recognition of examination results, and the implementation of AI in medical scenarios. It iterated and upgraded the construction and operation services of the Anhui provincial imaging cloud platform and replicated its mature platform architecture, operational experience, and ecosystem collaboration capabilities to other provinces. Currently, the Guangxi provincial cloud imaging project has been completed and implemented,

and related projects in multiple other provinces are progressing in an orderly manner. This effectively accelerates the implementation of the “national network” for medical insurance cloud imaging.

In Anhui Province, the Company has built the PRC’s largest regional platform for medical imaging data interoperability, sharing, and mutual recognition, and leverages the provincial imaging cloud platform to provide remote consultation and digital imaging services to all residents in the province. As of June 30, 2026, the Anhui provincial imaging cloud platform has connected over 1,980 medical institutions, covering nearly 100,000 physician workstations, has cumulatively aggregated over 160 million instances of imaging data, and provided over 12.7 million remote consultations and 90 million digital imaging services. The extensive institutional coverage, high-frequency clinical use, and continuous accumulation of imaging data collectively form the foundation for the platform to further expand value-added services such as intelligent quality control and imaging auxiliary diagnosis. The Company is currently actively exploring pan-imaging cloud services covering pathology, ECG, nuclear medicine, ultrasound, and endoscopy, as well as AI-SaaS service models, to further broaden its multi-layered and multi-scenario business models.

In February 2026, the Company won the bid for the Construction and Operation Project of the Imaging Cloud Platform of Guangxi Zhuang Autonomous Region, replicating and promoting the Anhui imaging cloud operation model nationwide. As of June 30, 2026, the platform had connected over 437 medical institutions, including over 370 Grade II and above hospitals, achieving 100% connectivity for all eligible Grade II and above hospitals. Currently, it covers over 70,000 physician workstations in Guangxi, with cumulative number of digital imaging services and data calls both exceeding 6.5 million. The project demonstrated outstanding delivery efficiency: the first hospital went live in 20 days, all tertiary hospitals were connected within 30 days, and full coverage of eligible secondary hospitals was completed in 90 days. It has become an industry benchmark case, recognized and featured in a special report by the National Healthcare Security Administration, and medical insurance departments from nine provinces (municipalities, autonomous regions) have visited for research and learning. Meanwhile, the Company is leveraging Guangxi’s geographical advantages to establish an ASEAN imaging sharing center, promoting the cross-border extension of imaging data interoperability and AI-assisted diagnosis services.

Leveraging the Xunfei Spark Medical Imaging Model, the Company continues to develop its intelligent imaging assistant, covering clinical processes such as intelligent quality control, intelligent image reading, and automatic report generation. Currently, the pilot application of AI report generation for certain modalities such as X-ray, CT, and MR has exceeded 900,000 cases, providing sufficient data support and scenario validation for the model's continuous iteration, optimization, and commercialization. Meanwhile, the Company has partnered with leading AI imaging vendors such as Shukun and InferVision to integrate their ecosystem partners' imaging auxiliary diagnosis services. It is exploring an annual service fee model based on disease types to continuously deepen the platform's value. As the number of connected institutions, accumulated imaging data, and clinical application scenarios continue to grow, the Company is gradually forming a business system with the platform as the entry point, data as the foundation, and AI as the incremental service. This lays the groundwork for participating in the construction of the national integrated medical insurance cloud imaging network and expanding sustainable operational space.

AI Post-discharge Patient Management: The Company has developed an AI-based post-discharge patient management platform. Through AI technology, it provides continuous, high-quality medical services to all hospital patients after discharge, addressing the gap in post-hospital care within the traditional healthcare system. Based on the Spark Medical Model, the platform analyzes all of a patient's clinical data during hospitalization. In accordance with relevant clinical guidelines and standards, and combined with the patient's personal health profile, it formulates and assists doctors in executing personalized rehabilitation management plans. Service scenarios cover the entire process, including health consultation, follow-up reminders, confirmation of follow-up data collection, medication guidance, rehabilitation education, and physician alerts for abnormal risk symptoms.

As the capabilities of the Spark Medical Model continue to iterate and upgrade, the platform can provide 7x24 interactive services with patients, supporting dialects from 14 provinces with a recognition accuracy of 92.3%. The platform adopts a tiered service model to precisely match patient needs: For patients with low-intervention needs, such as those with self-limiting diseases, the system automatically generates free rehabilitation management plans, providing basic services through regular AI phone follow-ups, follow-up reminders, and health education, and supports patients in initiating intelligent consultations at any time. For patients with key diseases that have a golden window for rehabilitation and complex recovery processes, the Company, in collaboration with hospitals, offers paid management services. It coordinates with the patient's attending physician, assigns health managers, and forms a patient management team to

provide patients with richer, continuous medical services such as text/image consultations, video consultations, and regular health assessments. As of now, the paid services have covered 158 disease types, reaching approximately 53% of discharged patients from leading provincial hospitals.

During the Reporting Period, the effectiveness of AI patient management and its outcomes continued to improve. The patient Net Promoter Score (NPS) increased from 50% last year to 56%, and the rehabilitation achievement rate for patients who purchased key disease-specific service packages remained above 96%. AI post-discharge patient management has established a tiered operational system ranging from free basic services to paid in-depth services, continuously driving growth in operating revenue and patient satisfaction. It provides a reusable and scalable practical paradigm for the refined development of smart hospitals and continuous, full-cycle patient health management.

Intelligent Medical Devices: The Company’s smart hearing aids are equipped with its self-developed adaptive scene recognition system, which can perceive the user’s environment in real time to precisely achieve core functions such as human voice enhancement and intelligent environmental noise reduction. Since the launch of its first in-ear hearing aid, the “Xiang Series (享系列)”, in 2022, the Company has continuously iterated its acoustic technology and product forms to meet market demand, successively launching multi-category products such as the “Hongyu Series (鴻語系列)” (behind-the-ear), the “Xing Series” (behind-the-ear), and the “Yue Series” (behind-the-ear Pro), thereby enhancing its product matrix for all-scenario hearing health.

In the first half of 2026, the Company completed a software iteration and upgrade for its core product “Xingyao (星耀),” and newly launched “Xingyao Pro (星耀Pro),” further optimizing the auditory experience and intelligent adaptation capabilities. As of June 30, 2026, the smart hearing aid business had established approximately 60 offline brand image stores and over 400 partner stores, creating an integrated online-to-offline marketing channel with continuously strengthening channel synergy.

In the home health field, the Company launched the iFLYTEK AI Cuff Blood Pressure Monitor X3/X5/X7 series products in April 2026. The products are equipped with the Spark Medical Model and innovatively integrate dual measurement algorithms of oscillometry and Korotkoff sound method, with a measurement error of only $\pm 2\text{mmHg}$, achieving in-hospital medical-grade accuracy. Leveraging the large model's capabilities, the equipment can generate personalized improvement plans based on personal health records, interpret blood pressure data in real time, and answer health questions, transforming into an exclusive virtual health manager that is "accurate, conversational, and analytical." This truly realizes a family health management model where "parents measure with ease, and children manage with convenience," marking the Company's gradual expansion from hearing health to the family health management field. The expansion of home-use intelligent medical devices not only provides users with reliable tools for continuous physiological indicator monitoring at home but also further enriches the data sources for personal health records, strengthening the data foundation for smart health services.

Xunfei Xiaoyi: During the Reporting Period, the Company continued to enhance its health consultation and management capabilities based on personal health records, providing users with more professional and authoritative health management services in the industry. While deepening its core product capabilities, Xunfei Xiaoyi continues to expand industrial ecosystem cooperation, deeply linking with primary healthcare institutions and hospitals at all levels to build a new paradigm of resident health management featuring "AI + family doctors + expert physicians". At the same time, it opens up and exports its medical large model technology capabilities to industry partners, creating an open, co-built, and shared medical and health ecosystem.

In February 2026, with the official release of the iFlytek Spark X2 Large Model, Xunfei Xiaoyi simultaneously completed the upgrade of the Spark Medical Model, achieving comprehensive improvements in health consultation capabilities such as multi-turn active inquiry, interpretation of examination and test reports, and interpretation of physical examination reports, thereby continuously consolidating its industry-leading advantage. As of June 30, 2026, the Xunfei Xiaoyi App had surpassed 35 million cumulative downloads and 200 million cumulative consultations. Through a comprehensive health profile and all-time health trajectory built with 170 types of tags, it now supports over 140 professional disease management pathways covering common chronic diseases in more than 20 departments, and has become a reliable digital tool for home-based rehabilitation and health management.

In March 2026, Xunfei Xiaoyi achieved a significant breakthrough in empowering regional family doctors. The Company, jointly with the Hainan Provincial Health Commission, launched “Ye Xiaoyi (椰曉醫),” deeply integrating AI family doctor capabilities into Hainan’s primary healthcare service system to build a one-stop smart health service system for residents featuring “24-hour health consultation, risk warnings, and health service plans.”

Meanwhile, Xunfei Xiaoyi continues to explore health management industry solutions for corporate clients such as pharmaceutical and insurance companies, continuously co-building new health management models with industry partners in areas like digital health management, chronic disease services, and employee health. In April 2026, Xunfei Healthcare signed a strategic cooperation agreement with CMRH Life. The two parties will fully leverage their core advantages in their respective fields, and through the comprehensive integration of technology, data, and ecosystems, jointly create a competitive “AI + Health + Insurance” innovative ecosystem. They will carry out comprehensive and systematic cooperation in areas such as corporate health management, refined services for specific diseases, and the intelligent upgrading of insurance services.

For the six months ended June 30, 2026, the Company recorded revenue of RMB182.4 million from AI Health Partner, representing an increase of 74.9% as compared to the same period in 2025, and accounting for 40.9% of its total revenue for the first half of 2026.

(3) *AI Digital Base: Actively Implementing National Strategic Directives*

Closely aligning with major national policy directives such as the “AI+” strategy and “Healthy China,” the Company has built a diversified AI Digital Base system covering provincial, municipal, district, and county levels. These solutions are precisely tailored to meet the operational needs and development goals of clients at different tiers, driving the digital and intelligent transformation of the healthcare sector.

For clients at the provincial, municipal, and county levels, the Company has developed three core digital bases that have achieved a market application landscape of broad coverage and deep implementation, as detailed below:

AI-Powered Urban Digital Base: The solution focuses on the reform and high-quality development of public hospitals. By deeply integrating medical big data with AI large models, it creates a “Resident Health Portrait” system that enables full-chain intelligent empowerment, from multi-source data integration, cleaning, and analysis to clinical decision support and health risk warning, providing precise data support for urban health management. Currently, the solution has been implemented in multiple cities, including Shanghai, Shenzhen, Hefei, Aksu, Jiuquan, and Yan’an. It builds a city-level collaborative platform for medical health data and intelligent services, fully unlocking the value of medical data to empower lifelong resident health management, while promoting the optimized allocation of medical resources and service coordination within regions. In May 2026, the Company took the lead in collaborating with entities such as Shanghai Municipality and the CAICT to formulate and release the PRC’s first standard specification for large model-based resident health portraits. In the same month, at the Chinese side event of the 79th World Health Assembly, the “Jing’an AI-Driven Resident Health Portrait” was selected as a benchmark case for digital health in the PRC and included in the typical case library of “Empowering Primary Health Services with Digital Intelligence — China’s Practice,” demonstrating a significant industry-wide exemplary effect.

AI Disease Control Digital Base: This solution has been implemented in four provinces: Shaanxi, Liaoning, Fujian, and Anhui. The contract value for the large model in both Shaanxi and Fujian provinces exceeded RMB10 million, leading the national market for large model digital bases in the public health sector. The solution leverages large model technology to enhance the capabilities of provincial disease control systems in surveillance and early warning, risk analysis, and emergency response. In the future, it is planned to be gradually extended to provincial disease control centers nationwide. In April 2026, the “Artificial Intelligence (AI)-Assisted Epidemiological Investigation System,” jointly developed by the Company and the Chinese Center for Disease Control and Prevention, won the Gold Award at the 2nd “Chuang Qing Chun (創青春)” National Youth Innovation Competition for the Health Industry. Concurrently, an agreement of intent for the industrialization of this technological achievement was signed on-site. Through the “New Generation Artificial Intelligence” major project under the Sci-Tech Innovation 2030 initiative, the Company has achieved significant technological breakthroughs in key areas such as speech recognition for epidemiological investigation scenarios, full-process intelligent human-computer interaction, and multi-modal intelligent data collection, thereby establishing a comprehensive intelligent epidemiological investigation

technology system. The signing of this industrialization agreement marks the official commencement of the nationwide, large-scale commercial promotion of this national-level research achievement.

AI Regional Collaborative Digital Base: Targeting the district and county levels, the Company is deeply involved in the planning, design, construction, and implementation of multiple projects focused on compact county-level medical communities, regional healthcare informatization, and primary healthcare capacity building (Strengthening Primary Healthcare Project). During the Reporting Period, the Company newly won bids for medical community and regional healthcare projects in areas such as Qingtongxia City and Weifang High-tech Zone, which are currently under steady construction. The Company will leverage its mature AI products and digital bases to help districts and counties integrate region-wide medical resources, optimize referral coordination mechanisms between different levels of care, and address the shortfalls in primary-level diagnostic and treatment capabilities, thereby continuously promoting the quality and efficiency of the county-level healthcare system and supporting its high-quality development.

For the six months ended June 30, 2026, the Company recorded revenue of RMB62.2 million from AI Digital Base, representing an increase of 7.9% as compared to the same period in 2025, and accounting for 13.9% of its total revenue for the first half of 2026.

III. SOCIAL RESPONSIBILITY, STRATEGIC COOPERATION, AND INDUSTRY RECOGNITION

Xunfei Healthcare embraces the philosophy of “Tech for Warm, AI for Love.” True to our founding mission of serving a Healthy China through artificial intelligence, we leverage core AI technologies to actively fulfill our corporate social responsibility across medical philanthropy, emergency assistance, and grassroots empowerment. By deeply integrating technological innovation with humanistic care, we contribute to national strategies and demonstrate, through concrete actions, the essence of tech for good — embodying the responsibility and commitment of a tech enterprise in the new era. Leveraging its clear development path and sustained technological barriers, the Company has received numerous authoritative industry awards, continuously consolidating its leading position. Its technological innovation and commercial value have been recognized by the capital market. The Company will, as always, remain true to its founding mission of safeguarding life and health with artificial intelligence, creating long-term value to reward its shareholders and society, and upholding the philosophy of “Tech for Warm, AI for Love.”

(1) *Social Philanthropy and Corporate Social Responsibility*

1. *Digital Healthy China Solution Presented at World Health Assembly, AI Resident Health Portrait Promoted Globally*

In May 2026, during the 79th World Health Assembly, the PRC, along with nine other countries including Brazil and Ethiopia, hosted a side event themed “Shaping Future Health Systems for Equity and Access in Digital Era.” Specially recommended by the National Health Commission, the AI-driven resident health portrait practice developed by Xunfei Healthcare was showcased as a benchmark case of primary digital health in the PRC, receiving widespread attention from international attendees. The project has covered over 1.49 million contracted residents in Shanghai and has been implemented in multiple other cities, including Shenzhen, Hefei, and Haikou. It has established a city-level health data collaboration platform, contributing a “China Solution” to global digital health governance.

2. *Proposals at the Two Sessions: “Using AI to Address Challenges in Chronic Disease Management and Rare Disease Prevention and Treatment”*

During the National Two Sessions in March 2026, LIU Qingfeng, a deputy to the NPC, focusing on essential public needs for AI, proposed two key healthcare recommendations: using AI to help basic public health services address challenges in chronic disease management and health services, and establishing an access and regulatory system for AI applications in basic public health to include AI health services in the public health catalog; and advancing the “AI + Rare Diseases” special project and application pilots to comprehensively enhance prevention and treatment support, by establishing a national “AI + Rare Diseases” special project and conducting application pilots to promote “early screening, early detection, and early treatment” at the grassroots level. These recommendations, closely aligned with the “Healthy China” initiative under the “15th Five-Year Plan,” reflect the Company’s deep engagement in policy foresight and its concern for public welfare.

3. *Xunfei Smart Hearing Aid Enhances Rural Hearing Health for Two Consecutive Years*

In January 2026, for the second consecutive year, the Xunfei Smart Hearing Aid was included in Liu Qiangdong's "New Year's Gifts for My Hometown (我給老家送年貨)" list. The initiative reached Guangming Village in Suqian, Jiangsu, providing free fitting services to over a thousand "left-behind" elderly residents. Featuring self-developed offline AI noise reduction technology, the product precisely addresses the pain points of rural hearing health. This represents the Company's ongoing practice of leveraging core technology to make inclusive healthcare more accessible to grassroots communities and serves as a warm testament to its "Tech for Good" philosophy.

(2) STRATEGIC COOPERATION AND BUSINESS PROGRESS

1. *Breakthrough in Overseas Strategy: Partnering with Indonesia's Sinar Mas Group to Deepen Presence in the Southeast Asian AI Healthcare Market*

Xunfei Healthcare entered into a strategic cooperation with PT DSST Mas Gemilang, a digital and intelligent infrastructure platform under Indonesia's Sinar Mas Group. The partnership innovatively adopts a "technology export + local ecosystem joint operation" model, where Xunfei Healthcare exports its full-stack AI medical technology and standardized solutions, while the Indonesian partner provides government and enterprise channels and localized operational support. The two parties will focus on core scenarios including AI systems for the full cycle of disease diagnosis and treatment, public health epidemic monitoring and early warning, and intelligent medical imaging. The cooperation will cover all levels of the Indonesian healthcare system. Xunfei Healthcare will use Indonesia as a strategic foothold to deepen its presence in the ASEAN market, continuously strengthening its strategic presence in the Southeast Asian digital and intelligent health industry.

2. *Benchmark in Full-Course Disease Management: Deepening Strategic Cooperation with Qilu Hospital of Shandong University*

Xunfei Healthcare signed a strategic cooperation agreement with Qilu Hospital of Shandong University to implement an intelligent follow-up platform centered on the jointly developed “Qilu-Spark Full-Course Disease Management Large Model.” The two parties leverage the AI large model to integrate in-hospital and out-of-hospital data, building a continuous health management service that covers pre-hospital education, in-hospital coordination, and post-hospital monitoring and rehabilitation guidance. This forms a virtuous service loop of “discovery-feedback-improvement-enhancement,” effectively improving the quality of medical services and the patient experience.

3. *Establishing Presence in Hong Kong Science Park: Partnering with ALPHA CARE and CTI to Develop the Longevity and Health Industry*

Xunfei Healthcare, in collaboration with ALPHA CARE and CTI, has officially established a tripartite deep strategic cooperation based in the Hong Kong Science Park. By integrating CTI’s high-quality testing data, ALPHA CARE’s professional health services, and Xunfei’s AI clinical knowledge system, the partnership will build a full-chain, closed-loop “Data + Expert Knowledge + Intelligent Services” model. Using Hong Kong as an international pilot, it aims to create an innovative and globally replicable health management model.

(3) AWARDS, HONORS, AND INDUSTRY RECOGNITION

1. *Leading a National Key Sci-Tech Project to Build an AI Defense Line for Public Health*

The national key sci-tech project led by Xunfei Healthcare, titled “AI Agent and Intelligent Warning Application System for Risk Assessment and Early Warning of New and Emerging Respiratory Infectious Diseases,” was officially launched. Based on the Spark Medical Model, the project will build a full-chain AI warning system integrating risk assessment, intelligent analysis, automatic warning, and closed-loop response, thereby enhancing the nation’s strategic biosecurity capabilities.

2. *Selected for the 2026 Future Healthcare Top 100, Highlighting Investment Value and Product Innovation*

At the Vbdata.cn 2026 Future Healthcare & Pharma Top 100 Conference, Xunfei Healthcare was named one of the “Top 50 Most Investment-worthy Enterprises in the PRC’s Healthcare Industry” for its GBC three-terminal, full-scenario closed-loop model; and the Xunfei Smart BTE Hearing Aid PRO was listed among the “Top 50 Most Innovative Products and Technologies in the PRC’s Healthcare Industry” for its pioneering multimodal subtitled hearing assistance and deep-sea level noise reduction technology. These dual honors affirm the Company’s leading position in the industry in terms of both capital market value and product technology.

3. *Selected as One of Sichuan’s First Batch of Typical Cases, Receiving Authoritative Endorsement for Grassroots Empowerment Achievements*

The Health Commission of Sichuan Province announced the first batch of “AI + Healthcare” typical cases, which included multiple cases jointly submitted by Xunfei Healthcare with Xichong County, Yanyuan County, and Yibin City. The cases cover scenarios such as primary care and imaging quality control, demonstrating quantifiable and replicable results in enhancing primary diagnostic capabilities, optimizing public health service efficiency, and promoting regional medical resource collaboration. This fully validates the capability for large-scale implementation of AI in empowering primary healthcare and provides a regional model for the standardized and normalized promotion of “AI + Healthcare.”

4. *Xunfei Healthcare Wins Two HKMA Global Innovation Awards, Receiving International Authoritative Recognition for its AI Innovation in Healthcare*

For its technological breakthroughs and large-scale implementation achievements in medical AI, Xunfei Healthcare won both the “Best in Healthcare Award” and the “Silver Award” at the “HKMA/HKT Global Innovation Award,” co-organized by the Hong Kong Management Association (HKMA) and HKT, becoming a key award winner in the healthcare track of the competition. The “Best in Healthcare Award” is the highest honor in the healthcare category, while the “Silver Award” is a high-level comprehensive award. Winning both awards affirms the Company’s professional depth in its vertical sector and the international competitiveness of its comprehensive innovation capabilities, accumulating authoritative brand endorsement for its global expansion.

5. *Xunfei Xiaoyi Selected for MIIT's "Typical Cases of Digital Products and Services for the Elderly and Disabled"*

The Ministry of Industry and Information Technology, together with five other departments including the Ministry of Civil Affairs, the Ministry of Transport, and the China Disabled Persons' Federation, announced the results of the "2025 Typical Cases of Digital Products and Services for the Elderly and Disabled" selection. Xunfei Xiaoyi stood out from hundreds of projects nationwide and was successfully selected as one of the 10 benchmark demonstrations in the innovative technology category, in recognition of its outstanding innovative practices in the age-friendly transformation of AI health services and accessible medical services. This selection signifies that the Company has received national-level authoritative recognition for fulfilling its "Tech for Good" mission and bridging the "digital divide."

FINANCIAL REVIEW

Revenue

The Company's total revenue increased by 49.4% from RMB298.6 million for the six months ended June 30, 2025 to RMB446.1 million for the six months ended June 30, 2026. Such increase was mainly attributable to the growth from AI Medical Assistant (47.5% year-on-year growth in revenue) and AI Health Partner (74.9% year-on-year growth in revenue).

Cost of sales

The Company's cost of sales increased by 45.1% from RMB144.7 million for the six months ended June 30, 2025 to RMB210.0 million for the six months ended June 30, 2026, primarily due to the increase in costs as revenue grew.

Gross profit and gross profit margin

The Company's gross profit increased by 53.5% from RMB153.9 million for the six months ended June 30, 2025 to RMB236.1 million for the six months ended June 30, 2026. The Company's gross profit margin was 51.5% and 52.9% for the six months ended June 30, 2025 and for the six months ended June 30, 2026, respectively, representing a small change.

Impairment losses under expected credit loss model, net of reversal

The Company's impairment losses under the expected credit loss model, net of reversal, increased by 329.9% from RMB3.2 million for the six months ended June 30, 2025 to RMB13.7 million for the six months ended June 30, 2026, primarily due to the increase in the balance of accounts receivable and the credit impairment loss rate during the period.

Other gains and losses

The Company recorded other gains of RMB5.2 million for the six months ended June 30, 2025, compared to other gains of nil for the six months ended June 30, 2026, primarily due to a decrease in foreign currency exchange gains.

Selling expenses

The Company's selling expenses increased by 0.1% from RMB102.1 million for the six months ended June 30, 2025 to RMB102.2 million for the six months ended June 30, 2026, remaining largely unchanged from the prior period.

Administrative expenses

The Company's administrative expenses decreased by 19.0% from RMB47.4 million for the six months ended June 30, 2025 to RMB38.4 million for the six months ended June 30, 2026, primarily due to a decrease in option costs and professional advisory fees.

Research and development expenses

The Company's research and development expenses increased by 32.2% from RMB114.5 million for the six months ended June 30, 2025 to RMB151.3 million for the six months ended June 30, 2026, primarily due to an increase in remuneration and intangible asset amortization.

Finance costs

The Company's finance costs decreased by 7.6% from RMB4.8 million for the six months ended June 30, 2025 to RMB4.5 million for the six months ended June 30, 2026, primarily due to a decrease in interest expense on borrowings.

Income tax credit

The Company's income tax credit amounted to RMB17.9 million and RMB19.5 million for the six months ended June 30, 2025 and for the six months ended June 30, 2026, respectively, primarily due to an increase in deferred income tax expense credit.

Loss for the period

Based on the foregoing, the Company's loss decreased by 41.5% from RMB82.3 million for the six months ended June 30, 2025 to RMB48.1 million for the six months ended June 30, 2026.

Non-IFRS measures

To supplement the Company's consolidated financial statements, which are presented in accordance with IFRS, the Company uses adjusted net loss for the period (non-IFRS measure) and adjusted net loss margin (non-IFRS measure) as additional financial measures, which are not required by, or presented in accordance with, IFRS. The Company believes that these non-IFRS measures help to compare operating results across periods and companies by eliminating the potential impacts of certain items. The Company believes that these non-IFRS measures, when presented in conjunction with the corresponding IFRS measures, provide useful information for potential investors and management by eliminating the potential impact of certain items, helping to compare the Company's operating performance across periods.

The Company defines adjusted loss for the period (non-IFRS measure) as loss for the period adjusted by adding back equity-settled share-based payments. Equity-settled share-based payments are non-cash in nature and mainly refer to arrangements where the Company receives employee services as consideration for equity instruments. Equity-settled share-based payments are not expected to result in future cash payments. Listing expenses are expenses for professional fees, underwriting commissions and other expenses incurred in connection with the Global Offering. The use of non-IFRS measures as analytical tools has limitations, and they should not be considered in isolation or as a substitute for or superior to analysis of the Company's operating results or financial condition as reported under IFRS. In addition, the definition of non-IFRS measures may differ from similarly titled terms used by other companies.

The following table is a reconciliation of adjusted net loss for the period (non-IFRS measure) and adjusted net loss margin (non-IFRS measure) for the periods indicated:

	Six months ended June 30,	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
Loss and total comprehensive expense for the period	(48,100)	(82,276)
Add: Equity-settled share-based payments	5,157	16,099
Adjusted net loss for the period (non-IFRS measure)	(42,943)	(66,177)
Adjusted net loss margin (non-IFRS measure) (%)	(9.6)	(22.2)

Liquidity and Sources of Funds

For the six months ended June 30, 2026, the Company primarily met its cash requirements through bank borrowings and cash generated from operations. As at June 30, 2026 and December 31, 2025, the Company's cash and cash equivalents were RMB163.1 million and RMB123.6 million, respectively. Cash and cash equivalents of the Group are mainly held in RMB as at June 30, 2026.

The following table sets forth the Company's cash flows for the periods indicated:

	Six months ended June 30,	
	2026	2025
	<i>RMB in</i>	<i>RMB in</i>
	<i>millions</i>	<i>millions</i>
Net cash used in operating activities	(181.6)	(169.2)
Net cash from (used in) investing activities	203.7	(24.2)
Net cash from financing activities	17.3	260.6
Net increase in cash and cash equivalents	39.5	67.2
Cash and cash equivalents at the beginning of the year	123.6	676.8
Cash and cash equivalents at the end of the period, presented as bank balances and cash	163.1	743.9

Looking ahead, the Company believes that it will be able to meet its liquidity requirements by using cash generated from operating activities.

Net cash used in operating activities

For the six months ended June 30, 2026, the Company's net cash used in operating activities was RMB181.6 million, primarily due to loss before tax of RMB67.6 million, as adjusted by the non-cash and non-operating items, primarily comprising an increase in amounts due from an associate of RMB225.7 million, and such cash outflow was partially offset by (i) an increase in contract liabilities and amounts due to shareholders of RMB55.7 million; (ii) other intangible asset amortization of RMB29.2 million. For the six months ended June 30, 2025, the Company's net cash used in operating activities was RMB169.2 million, primarily due to loss before tax of RMB100.1 million, as adjusted by the non-cash and non-operating items, primarily comprising an increase in trade and other receivables of RMB62.7 million, and such cash outflow was partially offset by (i) equity-settled share-based payments of RMB16.1 million; (ii) other intangible asset amortization of RMB16.3 million.

Net cash from/used in investing activities

For the six months ended June 30, 2026, the Company's net cash from investing activities was RMB203.7 million, primarily due to the recovery of time deposits of RMB240.0 million, as partially offset by the expenditure for acquisition of equipment and intangible assets of RMB41.3 million. For the six months ended June 30, 2025, the Company's net cash used in investing activities was RMB24.2 million, primarily due to the expenditure for acquisition of equipment and intangible assets of RMB28.1 million.

Net cash from financing activities

For the six months ended June 30, 2026, the Company's net cash from financing activities was RMB17.3 million, primarily due to bank borrowings raised of RMB94.6 million, as partially offset by the repayment of bank borrowings of RMB73.3 million. For the six months ended June 30, 2025, the Company's net cash from financing activities was RMB260.6 million, primarily due to bank borrowings raised of RMB351.9 million, as partially offset by the repayment of bank borrowings of RMB83.2 million.

Indebtedness

For the six months ended June 30, 2026, the Company had indebtedness in the form of bank borrowings and lease liabilities (both current and non-current). The Company did not have any outstanding mortgages, charges, debentures, other issued debt capital, bank overdrafts, borrowings, acceptance liabilities, or other similar indebtedness, any material guarantees, litigations, or claims that are pending or threatened against any member of our Group, or other material contingent liabilities.

Bank borrowings

As at June 30, 2026 and December 31, 2025, the Company's bank borrowings were RMB298.1 million and RMB276.8 million, respectively, which mainly refer to unsecured bank borrowings for working capital replenishment, all of which are repayable within three years. The Company's bank borrowings are all denominated in RMB. For the six months ended June 30, 2026, the interest rates of the Company's fixed-rate bank borrowings ranged from 2.11% to 2.40% per annum. As of August 18, 2026, the Company's unutilized committed banking facilities amounted to approximately RMB1,056.7 million.

Gearing ratio

As of June 30, 2026, the Company's gearing ratio based on total liabilities/total assets was 62.2%. As of December 31, 2025, the Company's gearing ratio was 59.0%.

Contingent liabilities

As of June 30, 2026, the Company did not have any material contingent liabilities (as at December 31, 2025: nil).

Capital expenditures

For the six months ended June 30, 2026, the Company's capital expenditures were RMB41.3 million, primarily due to purchases of fixed assets and intangible assets. The Company primarily funds its capital expenditure needs with borrowings and cash generated from sales.

Pledge of assets

As of June 30, 2026, the Company did not have any material pledge of assets (as at December 31, 2025: nil).

Material investments held

As of June 30, 2026, (i) the Group held a direct investment in Anhui Heshu Zhiyi Technology Co., Ltd.* (安徽省合數智醫科技有限公司) (“**Heshu Zhiyi**”) at a cost of approximately RMB186.7 million, representing a 49% equity interest; (ii) for the 6 months ended June 30, 2026, the Group recognised its share of relevant losses attributable to Heshu Zhiyi of approximately RMB5.5 million; (iii) for the 6 months ended June 30, 2026, the Group recognised unrealised gains on transactions with Heshu Zhiyi of RMB56.2 million; (iv) no dividend/profit distribution was received during the 6 months ended June 30, 2026. The book value of the investment in Heshu Zhiyi was RMB122.1 million, representing approximately 5.1% of the Group's total assets as at June 30, 2026. Heshu Zhiyi is a technology company focused on the construction and operation of pilot bases for medical artificial intelligence applications. Considering its core business and development prospects, the Group expects to receive financial returns from its investment in Heshu Zhiyi.

Future plans for material investments and capital assets

As of June 30, 2026, the Company did not have other plans for material investments and capital assets (as at December 31, 2025: nil).

* For identification purposes only

Material acquisitions and/or disposals of subsidiaries and affiliated companies

Reference is made to the announcement of the Company dated June 18, 2026 in relation to the deemed disposal of the subsidiary (the “**Announcement**”). Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Announcement.

On June 18, 2026 (after trading hours), the Existing Shareholders (including the Company) and Sanya Gaozhuo Jiayin entered into the Investment Agreement, pursuant to which, the parties agreed that Sanya Gaozhuo Jiayin shall pay RMB1,527,500 to Beijing Huiji to subscribe for the new registered capital of RMB1,294,500 of Beijing Huiji, and the balance (i.e., RMB233,000) will be credited to the capital reserve of Beijing Huiji. Upon completion of the capital contribution, the registered capital of Beijing Huiji will increase from RMB20,280,000 to RMB21,574,500, and the Company’s equity interest in Beijing Huiji will decrease from 52.13% to 49.00%. Notwithstanding the foregoing, as the Company will maintain effective control over Beijing Huiji, its financial results will continue to be consolidated into the Company’s consolidated financial statements.

Upon completion of the Investment Agreement, the Company’s equity interest in Beijing Huiji will decrease from 52.13% to 49.00%. Therefore, the Investment Agreement constitutes a deemed disposal of the Company under Rule 14.29 of the Listing Rules.

For details, please refer to the Announcement.

Save as disclosed above, for the six months ended June 30, 2026, the Company did not have any material acquisitions and/or disposals of subsidiaries and affiliated companies.

Foreign exchange risk

The functional currency of the Company’s entities is RMB. During the Reporting Period, the Company primarily operated its business in the PRC. The Company does not currently have a foreign exchange hedging policy. However, the Company’s management monitors foreign exchange risks and will consider hedging significant foreign exchange risks when necessary.

FUTURE OUTLOOK

Adhering to a long-term philosophy and insisting on independent innovation in core source technologies, the Company, through long-term technological development and industry expertise, has grown into a leading enterprise in the PRC’s AI healthcare sector, with an extensive business footprint and a market share that is consistently among the top in the industry. The Company has always been guided by its mission to be “an AI Medical Assistant for every doctor and an AI Health Partner for everyone,” continuously deepening

its focus on the intelligent healthcare sector, concentrating on core product value, and steadily expanding its industry-leading advantages.

Looking ahead, the Company will remain steadfast in its healthcare mission and vision, further clarify its business objectives, and focus on its core activities. In terms of AI Medical Assistant, the Company will leverage the advantages of its Hefei base, using the General Practice CDSS to penetrate the primary care market and establish nationwide control over the primary care sector. In terms of the AI Health Partner, the Company will continue to deepen its patient operation business system, focusing on refined operations to create a stable and profitable growth model, while continuously expanding its coverage of top-tier hospitals; and further explore multi-level, multi-scenario business models, from digital imaging services to pan-imaging cloud and AI-SaaS imaging. The Company will also leverage the organic combination of the real economy and financial capital to steadily expand its market coverage, explore new opportunities in AI healthcare, and advance steadily in the wave of digital health. By delivering health care through technology and fulfilling its social responsibilities with commitment, the Company will continue to create value for its shareholders.

Employees, Training, and Remuneration Policies

As of June 30, 2026, our Group had 1,045 full-time employees (December 31, 2025: 1,045), most of whom are based in Hefei City, Anhui Province, China.

The remuneration package of employees generally includes basic salary and performance-based bonus. In general, the Group determines the remuneration package based on the qualifications, position and performance of its employees.

The Company provides employees with an insurance package consisting of pension insurance, maternity insurance, unemployment insurance, work-related injury insurance, medical insurance and housing funds, as required by Chinese laws and regulations. The Company offers a flexible work system to accommodate employees' flexible work needs and strictly enforce work hours and vacation policies to enhance work efficiency and employee satisfaction. The Company's dismissal procedures are structured to ensure fairness and legality. They include clear guidelines on performance management, regular feedback sessions, and a structured grievance redressal mechanism that employees can use to contest decisions or seek clarification. In addition, the Company maintains a zero-tolerance policy towards discrimination and harassment in the workplace. This policy is supported by mandatory training sessions on diversity and inclusion for all employees, regular reviews of workplace practices, and a confidential reporting system for any incidents of discrimination or harassment. The Company also regularly organizes health and safety training programs to improve employees' first aid knowledge and skills.

For the six months ended June 30, 2026, our total employee compensation and benefits expenses were RMB194.5 million.

The Group has adopted a share ownership plan to attract and retain the talents and to provide incentives to employees of our Group and talents who have made contribution to the development of our Group, for long-term development of our Company. Details of the share ownership plan are set out in the Prospectus.

The remuneration of the Directors and senior management is recommended by the Remuneration Committee and approved by the Board. The corporate goals and objectives set by the Board, the remuneration paid by comparable companies, the time and responsibilities committed by the Directors, and the employment conditions of other positions within the Group are taken into consideration in determining the remuneration of the Directors and senior management.

Subsequent Events

There were no other material events subsequent to the Reporting Period and up to the date of this announcement that would likely have a significant impact on the Group.

**CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND
OTHER COMPREHENSIVE INCOME**
FOR THE SIX MONTHS ENDED JUNE 30, 2026

		Six months ended June 30,	
	<i>NOTES</i>	2026	2025
		RMB'000	RMB'000
		(unaudited)	(unaudited)
Revenue	4	446,116	298,552
Cost of sales		(210,005)	(144,684)
Gross profit		236,111	153,868
Other income		11,904	12,797
Impairment losses (including reversals of impairment losses) on financial assets		(13,681)	(3,182)
Other gains and losses		(36)	5,166
Selling expenses		(102,183)	(102,060)
Administrative expenses		(38,414)	(47,399)
Research and development expenses		(151,326)	(114,505)
Share of results of an associate		(5,545)	—
Finance costs		(4,454)	(4,819)
Loss before tax	6	(67,624)	(100,134)
Income tax credit	5	19,524	17,858
Loss and total comprehensive expense for the period		<u>(48,100)</u>	<u>(82,276)</u>
(Loss) profit and total comprehensive (expense) income attributable to:			
— Owners of the Company		(59,303)	(74,086)
— Non-controlling interests		11,203	(8,190)
		<u>(48,100)</u>	<u>(82,276)</u>
Loss per share			
— Basic (RMB yuan)	8	<u>(0.49)</u>	<u>(0.61)</u>

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT JUNE 30, 2026

	<i>NOTE</i>	June 30, 2026 <i>RMB'000</i> (unaudited)	December 31, 2025 <i>RMB'000</i> (audited)
Non-current assets			
Equipment		113,408	20,149
Right-of-use assets		3,745	5,264
Goodwill		23,777	23,777
Other intangible assets		193,669	179,483
Interests in an associate		122,079	162,082
Equity instruments at fair value through other comprehensive income (“FVTOCI”)		2,731	2,731
Deferred tax assets		186,504	168,043
Long-term trade receivables		40,984	42,118
Deposit for acquisition of equipment		—	26,466
		686,897	630,113
Current assets			
Inventories		144,445	131,436
Bills, trade and other receivables	9	1,039,501	1,082,012
Contract assets		35,999	35,919
Amount due from the ultimate holding company		4,017	3,204
Amounts due from fellow subsidiaries		103,005	53,424
Amount due from an associate		235,052	9,332
Pledged/restricted bank deposits		1,943	2,143
Time deposits		—	241,176
Cash and cash equivalents		163,132	123,636
		1,727,094	1,682,282

	<i>NOTES</i>	June 30, 2026 RMB'000 (unaudited)	December 31, 2025 RMB'000 (audited)
Current liabilities			
Bills, trade and other payables	10	728,492	683,823
Bank borrowings		250,600	140,600
Amount due to the ultimate holding company		162,031	127,998
Amounts due to related companies		111,710	108,794
Lease liabilities		3,397	4,072
Provision		91,650	86,364
Contract liabilities		48,734	27,112
Deferred income		193	8,836
Tax liabilities		1,721	1,789
		<u>1,398,528</u>	<u>1,189,388</u>
Net current assets		<u>328,566</u>	<u>492,894</u>
Total assets less current liabilities		<u>1,015,463</u>	<u>1,123,007</u>
Non-current liabilities			
Lease liabilities		1,749	2,166
Deferred income		31,638	24,901
Bank borrowings		47,500	136,150
Long term payables	10	11,797	—
Deferred tax liabilities		10,862	11,930
		<u>103,546</u>	<u>175,147</u>
Net assets		<u><u>911,917</u></u>	<u><u>947,860</u></u>
Capital and reserves			
Share capital		120,879	120,879
Reserves		735,815	775,697
		<u>856,694</u>	<u>896,576</u>
Equity attributable to owners of the Company		856,694	896,576
Non-controlling interests		55,223	51,284
		<u>911,917</u>	<u>947,860</u>
Total equity		<u><u>911,917</u></u>	<u><u>947,860</u></u>

1. GENERAL INFORMATION

Xunfei Healthcare Technology Co., Ltd. (訊飛醫療科技股份有限公司) (the “**Company**”), formerly known as Anhui Xunfei Medical Co., Ltd. (安徽訊飛醫療股份有限公司), Anhui iFLYTEK Medical Information Technology Company Limited (安徽科大訊飛醫療信息技術有限公司) and Anhui Puji Information Technology Company Limited (安徽普濟信息科技有限公司), was established as a company with limited liability in Hefei City, Anhui Province, the PRC, on May 13, 2016, under the Company Law of the PRC. The immediate holding company and the ultimate holding company of the Company is iFLYTEK. The address of the registered office and the principal place of business of the Company is 4 to 5/F (North Area), No.1 Building, iFLYTEK AI Research and Development Production Base (Phase I), No. 666 Science and Innovation Road, Chengxiqiao Community Services Center, High-tech Zone, Hefei City, Anhui Province, PRC.

On December 24, 2021, the Company was converted into a joint stock company with limited liability. The Company’s shares were listed on the Main Board of The Stock Exchange of Hong Kong Limited on December 30, 2024 (the “**Listing**”).

The Group are principally engaged in the provision of comprehensive healthcare AI solutions in the PRC.

The condensed consolidated financial statements are presented in Renminbi (“**RMB**”), which is also the functional currency of the Company and its subsidiaries.

2. BASIS OF PREPARATION

The condensed consolidated financial statements have been prepared in accordance with International Accounting Standards 34 (“**IAS 34**”) as issued by the International Accounting Standards Board (“**IASB**”) as well as with the applicable disclosure requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The directors of the Company have, at the time of approving the condensed consolidated financial statements, a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Thus, they continue to adopt the going concern basis of accounting in preparing the condensed consolidated financial statements.

3. ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for FVTOCI, which is measured at revalued amounts or fair values.

Other than additional in accounting policies resulting from application of amendments to IFRS Accounting Standards, the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2026 are the same as those presented in the Group's annual consolidated financial statements for the year ended 31 December 2025.

Application of amendments to IFRS Accounting Standards

In the current interim period, the Group has applied the following amendments to IFRS Accounting Standards as issued by the IASB, for the first time, which are mandatorily effective for the Group's annual period beginning on January 1, 2026 for the preparation of the Group's condensed consolidated financial statements:

Amendments to IFRS 9 and IFRS 7	Amendments to the Classification and Measurement of Financial Instruments
Amendments to IFRS 9 and IFRS 7	Contracts Referencing Nature-dependent Electricity
Amendments to IFRS Accounting Standards	Annual Improvements to IFRS Accounting Standards — Volume 11

The application of the amendments to IFRS Accounting Standards in the current interim period has had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

4. REVENUE AND SEGMENT INFORMATION

(i) Disaggregation of revenue from contracts with customers

	Six months ended June 30,	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(unaudited)	(unaudited)
Types of goods or services		
Project implementation services	393,257	238,425
Operation services	26,070	23,580
AI healthcare products	26,789	36,547
	<u>446,116</u>	<u>298,552</u>
By business lines		
AI Medical Assistant	201,562	136,674
AI Health Partner	182,387	104,253
AI Digital Base	62,167	57,625
	<u>446,116</u>	<u>298,552</u>
Timing of revenue recognition		
A point in time	420,046	274,972
Overtime	26,070	23,580
	<u>446,116</u>	<u>298,552</u>

(ii) Segment Information

Information is reported to the executive director of the Company, being the chief operating decision maker (“CODM”), for the purposes of resource allocation and performance assessment. The accounting policies are the same as the Group’s accounting policies described in Note 3. No other analysis of the Group’s results nor assets and liabilities is regularly provided to the CODM for review and the CODM reviews the overall results and financial position of the Group as a whole. Accordingly, the CODM has identified one operating segment and only entity-wide disclosures, major customers and geographical information are presented in accordance with IFRS 8 *Operating Segments*.

Geographical information

The Group primarily operates in the PRC. The Group’s non-current assets are all located in the PRC.

Information about major customers

Revenue from customers of the corresponding periods contributing over 10% of the total revenue of the Group are as follows:

	Six months ended June 30,	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(unaudited)	(unaudited)
Customer A	163,022	—
Customer B	57,806	39,028

5. INCOME TAX CREDIT

	Six months ended June 30,	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(unaudited)	(unaudited)
Current tax	—	—
Deferred tax	(19,524)	(17,858)
	(19,524)	(17,858)

6. LOSS BEFORE TAX

Loss for the year has been arrived at after charging:

	Six months ended June 30,	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(unaudited)	(unaudited)
Directors' remuneration	2,440	6,643
Other staff:		
Salaries, discretionary bonus and other benefits	173,023	137,987
Retirement benefit scheme contributions	14,572	11,416
Equity-settled share-based payments	4,420	11,529
Total staff costs	194,455	167,575
Less: Capitalised in development costs	(13,976)	(8,557)
	180,479	159,018
Depreciation of equipment	9,081	3,024
Depreciation of right-of-use assets	1,519	1,519
Amortization of other intangible assets	26,602	16,344
Total depreciation and amortization	37,202	20,887

7. DIVIDENDS

No dividend was paid, declared or proposed during the six months ended June 30, 2026 (six months ended June 30, 2025: nil). The directors of the Company have determined that no dividend will be paid in respect of the interim period (six months ended June 30, 2025: nil).

8. LOSS PER SHARE

The calculation of the basic loss per share attributable to owners of the Company is based on the following data:

	Six months ended June 30,	
	2026	2025
	'000	'000
	(unaudited)	(unaudited)
Loss for the purposes of calculating basic loss per share attributable to owners of the Company (<i>RMB</i>)	<u>(59,303)</u>	<u>(74,086)</u>
Weighted average number of ordinary shares for the purpose of basic loss per share calculation	<u>120,879</u>	<u>120,879</u>

The potential ordinary shares arising from restricted shares scheme were not included in the calculation of diluted losses per share for both periods, as their inclusion would be anti-dilutive.

9. BILLS, TRADE AND OTHER RECEIVABLES

	June 30,	December 31,
	2026	2025
	<i>RMB</i>'000	<i>RMB</i>'000
	(unaudited)	(audited)
Trade receivables	1,018,076	1,072,402
Bills receivables	4,268	—
Less: allowance for credit losses	<u>(68,436)</u>	<u>(56,549)</u>
	953,908	1,015,853
Other receivables	17,308	15,502
Advance to suppliers	50,744	38,752
Tax recoverable	215	88
Other tax recoverable	<u>17,326</u>	<u>11,817</u>
	<u>1,039,501</u>	<u>1,082,012</u>

The following is an aged analysis of trade receivables net of allowance for credit losses presented based on invoice dates:

	June 30, 2026 RMB'000 (unaudited)	December 31, 2025 RMB'000 (audited)
0–90 days	128,017	307,486
91–180 days	72,674	63,538
181–365 days	263,160	147,219
1–2 years	219,056	221,093
2–3 years	88,561	98,278
Over 3 years	178,172	178,239
	949,640	1,015,853

10. BILLS, TRADE AND OTHER PAYABLES

	June 30, 2026 RMB'000 (unaudited)	December 31, 2025 RMB'000 (audited)
Trade payables	460,728	481,084
Bills payables	197,363	78,335
Total trade and bills payables	658,091	559,419
Payroll payables	41,654	62,426
Value-added tax and other tax payables	36,107	50,526
Others	4,437	11,452
	740,289	683,823
Less: Amounts due for settlement after one year shown under long-term payables	11,797	—
	728,492	683,823

The credit period of trade creditors is generally 30 days. The following is an aged analysis of trade payables presented based on the invoice dates:

	June 30, 2026 RMB'000 (unaudited)	December 31, 2025 RMB'000 (audited)
0–90 days	135,440	221,422
91–180 days	105,503	35,095
181–365 days	70,756	49,510
Over 1 year	149,029	175,057
	<u>460,728</u>	<u>481,084</u>

The following is an aged analysis of bills payables based on the bill issuance dates at the end of each reporting period:

	June 30, 2026 RMB'000 (unaudited)	December 31, 2025 RMB'000 (audited)
0–180 days	<u>197,363</u>	<u>78,335</u>

OTHER INFORMATION

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

Our Company is committed to maintaining high standards of corporate governance to protect shareholders' interests, enhance corporate value, and ensure accountability. The Company has adopted the Corporate Governance Code (the “**CG Code**”) as set out in Appendix C1 to the Listing Rules as its own code of corporate governance. To the best of the Directors' knowledge, our Company has complied with the applicable code provisions set out in Part 2 of the Corporate Governance Code during the six months ended June 30, 2026.

The Board will continue to review and monitor the Company's corporate governance practices to ensure compliance with the CG Code and maintain high standards of corporate governance.

COMPLIANCE WITH THE MODEL CODE

Our Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the “**Model Code**”) as set out in Appendix C3 to the Listing Rules as the code for securities transactions by Directors.

Each of the Directors has confirmed, after making specific inquiries of all Directors, that they have complied with the Model Code during the six months ended June 30, 2026.

SCOPE OF WORK OF MESSRS. DELOITTE TOUCHE TOHMATSU

The Group's auditor, Messrs. Deloitte Touche Tohmatsu, has carried out a review of the condensed consolidated financial statements of the Group for the six months ended June 30, 2026 in accordance with Hong Kong Standard on Review Engagements 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Hong Kong Institute of Certified Public Accountants.

AUDIT COMMITTEE

The Company has established the Audit Committee in accordance with Rule 3.21 of the Listing Rules and the CG Code. The Audit Committee comprises three members, namely Prof. Zhao Huifang (趙惠芳), Prof. Wang Yang (汪揚) and Mr. Duan Dawei (段大為), with Prof. Zhao Huifang (who is an independent non-executive Director of the Company with appropriate professional qualifications) acting as the chairman of the Audit Committee.

The Audit Committee has reviewed the unaudited consolidated financial statements of the Group for the six months ended June 30, 2026 and has discussed with senior management and the Auditor matters relating to the accounting policies and practices and internal controls adopted by the Company.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended June 30, 2026, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's securities (including the sale of treasury shares (as defined under the Listing Rules)). The Company did not hold any treasury shares as of June 30, 2026.

DIVIDENDS

The Board has resolved not to declare an interim dividend for the six months ended June 30, 2026 (for the six months ended June 30, 2025: nil).

USE OF PROCEEDS FROM THE LISTING

Our Company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2024 (the “**Listing**”), issuing 7,035,550 new shares at an offer price of HK\$82.80 per share, with net proceeds from the Listing of approximately HK\$507.1 million after deducting underwriting commissions, fees and other expenses related to the Global Offering. The proceeds from the Listing will be utilized in accordance with the plans disclosed in the section headed “Future Plans and Use of Proceeds” in the Prospectus, namely:

Item	Percentage %	Proceeds to be used for related purpose and unutilized proceeds as at the beginning of the Reporting Period (HK\$ in millions)	Utilized proceeds during the Reporting Period (HK\$ in millions)	Unutilized proceeds as of the end of the Reporting Period (HK\$ in millions)	Expected timetable for the fully utilizing of unutilized proceeds
Investing in research and development to continuously reinforce our core competence	32.3	83.2	56.6	26.6	By the end of December 2026
Further enriching our products and services through upgrading existing products and developing new products	26.6	68.3	52.3	16.0	By the end of December 2026
Reinforcing our commercialization capabilities and expand our service network	24.7	74.9	40.1	34.8	By the end of December 2026
Acquiring companies that may generate synergy with our existing capacities, such as medical device manufactures.	6.4	32.3	—	32.3	By the end of December 2026
Working capital and other general corporate purposes	10.0	1.6	—	1.6	By the end of December 2026
Total	100	260.3	149.0	111.3	

Note: The expected timetable for the fully utilizing of unutilized proceeds was based on the estimate of the Group, which is subject to the current and future development of the market conditions.

The Company has placed the net proceeds that have not yet been utilized in short-term interest-bearing accounts with licensed commercial banks and/or other authorized financial institutions. The Company will comply with PRC laws regarding foreign exchange registration and remittance of proceeds.

PUBLICATION OF INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

The interim results announcement will be published on the websites of the Hong Kong Stock Exchange (www.hkexnews.hk) and the Company (www.iflyhealth.com). The interim report of the Company for the six months ended 30 June 2026 will be published on the websites of the Hong Kong Stock Exchange and the Company in due course.

By order of the Board
Xunfei Healthcare Technology Co., Ltd.
Dr. Tao Xiaodong
Executive Director

Hong Kong, August 18, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Dr. Tao Xiaodong as executive director; (ii) Dr. Liu Qingfeng, Mr. Zhao Zhiwei and Mr. Duan Dawei as non-executive directors; and (iii) Prof. Wang Yang, Prof. Zhao Huifang and Mr. Tan Ching as independent non-executive directors.